Boston Pharmaceuticals Unveils Data at EASL Congress 2024 Demonstrating BOS-580, a Long-acting FGF21 Analogue, Enhances Lipid Profiles in Phenotypic MASH Patients.

Nutcracker Therapeutics Showcases Improved Efficacy of B Cell Lymphoma Drug Candidate NTX-472 at 2024 ASCO Meeting.

Accutar Biotechnology, Inc. has shared findings from an ongoing Phase 1 clinical trial of AC699.

The European Commission has approved Biogen's QALSODY® (tofersen), a pioneering treatment for a rare genetic type of ALS.

Immunocore reveals new Phase 1 results for brenetafusp (IMC-F106C), a bispecific ImmTAC targeting PRAME, in melanoma patients previously treated with immune checkpoint inhibitors at ASCO 2024.

Actym Therapeutics revealed that the U.S. FDA allowing the commencement of a Phase 1 clinical trial for its primary drug candidate, ACTM-838.

U.W. FDA recognizes Astellas' resubmitted biologics license application for zolbetuximab and establishes a new target date.

This TROPiCS-04 trial compared the effects of Trodelvy (sacituzumab govitecan-hziy; SG) against single-agent chemotherapy in individuals with metastatic urothelial carcinoma (mUC).

Ivonescimab plus chemotherapy approved by NMPA for 2L+ EGFRm NSCLC in China: HARMONi-A Trial shows positive overall survival trend for the combination.

TransCode Therapeutics Announces Positive Data from Initial Human Trial of New Lead Therapy Candidate, TTX-MC138.

Biohaven administers initial dose of new Trop-2 targeting ADC BHV-1510 to patient with advanced or metastatic epithelial cancers.

Full-Life Technologies Gets FDA Nod for IND Application of 225Ac-FL-020 in Treating Metastatic Castration-Resistant Prostate Cancer.